Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Motor Neuron Disease, Amyotrophic Lateral Sclerosis Clear all
Withdrawn No phase listed Observational

A Study to Explore the Role of Gut Flora in ALS

NCT04150809
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 14, 2026, 11:38 AM EDT
Recruiting Not applicable Interventional

Spinal Cord Associative Plasticity for ALS

NCT06172621
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Spinal Cord Associative Plasticity (SCAP), Upper extremity task-oriented exercise
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 14, 2026, 11:38 AM EDT
Terminated No phase listed Observational

Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient

NCT00718016
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 14, 2026, 11:38 AM EDT
Recruiting Not applicable Interventional

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study

NCT07543367
View directory record Official record
Conditions
Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis, ALS
Interventions
Stentrode
Device
Lead sponsor
Synchron, Inc.
Industry
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Jacksonville, Florida • Buffalo, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 14, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

ALS Reversals - Lunasin Regimen

NCT02709330
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Lunasin Regimen, Historical control
Drug · Other
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 14, 2026, 11:38 AM EDT
Active, not recruiting Phase 2 Interventional

T-regulatory Cells in ALS

NCT04055623
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 14, 2026, 11:38 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

NCT03334786
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Fasciculation
Interventions
FLX-787-ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 14, 2026, 11:38 AM EDT
Completed No phase listed Observational

Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis

NCT00339976
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 11:38 AM EDT
Completed No phase listed Observational

Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS)

NCT00838617
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 14, 2026, 11:38 AM EDT
Completed No phase listed Observational

Collection of Blood Samples for DNA in Motor Neuron Disease

NCT00362362
View directory record Official record
Conditions
Motor Neuron Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 14, 2026, 11:38 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)

NCT01950910
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 14, 2026, 11:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Remote Speech and Swallowing Assessment in ALS

NCT04889898
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone, Modified Barium Swallow Study (MBSS), Speech Intelligibility Test (SIT), SIT Scoring
Device · Radiation · Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 14, 2026, 11:38 AM EDT
Completed No phase listed Observational

Delineating Swallowing Impairment and Decline in ALS

NCT02962050
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Videofluoroscopic Swallowing Study (VFSS), Voluntary Peak Cough Flow Testing, Iowa Oral Performance Instrument, Capsaicin Challenge, Pulmonary Function Testing, Eating Assessment Tool 10, The Center for Neurologic Study Bulbar Function Scale
Procedure · Device · Drug + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 14, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

NCT00875446
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PLACEBO, GSK1223249
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 14, 2026, 11:38 AM EDT
Completed Phase 2Phase 3 Interventional

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04516096
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 14, 2026, 11:38 AM EDT
Suspended Phase 1 Interventional

Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis

NCT01082653
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous bone marrow-derived stem cells
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 14, 2026, 11:38 AM EDT
Not listed Not applicable Interventional

Telehealth Implementation of Brain-Computer Interface

NCT05951556
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Stroke
Interventions
Use of BCI
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
16 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 14, 2026, 11:38 AM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 14, 2026, 11:38 AM EDT
Recruiting Phase 1 Interventional

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165
View directory record Official record
Conditions
ALS
Interventions
AMX0114, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 14, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT01142856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous mesenchymal stem cells
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 14, 2026, 11:38 AM EDT
Terminated Phase 3 Interventional

Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)

NCT01016522
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
KetoCal
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 14, 2026, 11:38 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

NCT05442775
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Reldesemtiv
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 14, 2026, 11:38 AM EDT
Not listed Phase 1 Interventional

CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS

NCT03049046
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CC100, Placebos
Drug
Lead sponsor
Chemigen, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 14, 2026, 11:38 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT05237284
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SAR443820, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 14, 2026, 11:38 AM EDT